Research programme: glucocorticoid receptor modulators - Karo Pharma/Zydus Cadila

Drug Profile

Research programme: glucocorticoid receptor modulators - Karo Pharma/Zydus Cadila

Latest Information Update: 21 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio; Zydus Cadila
  • Class Glucocorticoids
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 02 Apr 2012 Discontinued - Preclinical for Inflammation in India (unspecified route)
  • 02 Apr 2012 Discontinued - Preclinical for Inflammation in Sweden (unspecified route)
  • 21 Mar 2011 Karo Bio and Zydus Cadila extend their research agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top